First step towards synthetic CO2 fixation in living cells – EurekAlert

image:

Researchers at the MPI for Terrestrial Microbiology have designed and constructed a new synthetic CO2-fixation pathway, the so-called THETA cycle.

Credit: Max Planck Institute for Terrestrial Microbiology/Geisel

Synthetic biology offers the opportunity to build biochemical pathways for the capture and conversion of carbon dioxide (CO2). Researchers at the Max-Planck-Institute for Terrestrial Microbiology have developed a synthetic biochemical cycle that directly converts CO2 into the central building block Acetyl-CoA. The researchers were able to implement each of the three cycle modules in the bacterium E.coli, which represents a major step towards realizing synthetic CO2 fixing pathways within the context of living cells.

Developing new ways for the capture and conversion of CO2 is key to tackle the climate emergency. Synthetic biology opens avenues for designing new-to-nature CO2-fixation pathways that capture CO2 more efficiently than those developed by nature. However, realizing those new-to-nature pathways in different in vitro and in vivo systems is still a fundamental challenge. Now, researchers in Tobias Erb's group have designed and constructed a new synthetic CO2-fixation pathway, the so-called THETA cycle. It contains several central metabolites as intermediates, and with the central building block, acetyl-CoA, as its output. This characteristic makes it possible to be divided into modules and integrated into the central metabolism of E. coli.

The entire THETA cycle involves 17 biocatalysts, and was designed around the two fastest CO2-fixing enzymes known to date: crotonyl-CoA carboxylase/reductase and phosphoenolpyruvate carboxylase. The researchers found these powerful biocatalysts in bacteria. Although each of the carboxylases can capture CO2 more than 10 times faster than RubisCO, the CO2-fixing enzyme in chloroplasts, evolution itself has not brought these capable enzymes together in natural photosynthesis.

The THETA cycle converts two CO2 molecules into one acetyl-CoA in one cycle. Acetyl-CoA is a central metabolite in almost all cellular metabolism and serves as the building block for a wide array of vital biomolecules, including biofuels, biomaterials, and pharmaceuticals, making it a compound of great interest in biotechnological applications. Upon constructing the cycle in test tubes, the researchers could confirm its functionality. Then the training began: through rational and machine learning-guided optimization over several rounds of experiments, the team was able to improve the acetyl-CoA yield by a factor of 100. In order to test its in vivo feasibility, incorporation into the living cell should be carried out step by step. To this end, the researchers divided the THETA cycle into three modules, each of which was successfully implemented into the bacterium E. coli. The functionality of these modules was verified through growth-coupled selection and/or isotopic labelling.

"What is special about this cycle is that it contains several intermediates that serve as central metabolites in the bacterium's metabolism. This overlap offers the opportunity to develop a modular approach for its implementation. explains Shanshan Luo, lead author of the study. We were able to demonstrate the functionality of the three individual modules in E. coli. However, we have not yet succeeded in closing the entire cycle so that E. coli can grow completely with CO2," she adds. Closing the THETA cycle is still a major challenge, as all of the 17 reactions need to be synchronized with the natural metabolism of E. coli, which naturally involves hundreds to thousands of reactions. However, demonstrating the whole cycle in vivo is not the only goal, the researcher emphasizes. "Our cycle has the potential to become a versatile platform for producing valuable compounds directly from CO2 through extending its output molecule, acetyl-CoA." says Shanshan Luo.

Bringing parts of the THETA cycle into living cells is an important proof-of-principle for synthetic biology, adds Tobias Erb. Such modular implementation of this cycle in E. coli paves the way to the realization of highly complex, orthogonal new-to-nature CO2-fixation pathways in cell factories. We are learning to completely reprogram the cellular metabolism to create a synthetic autotrophic operating system for the cell."

Cells

Construction and modular implementation of the THETA cycle for synthetic CO2 fixation. Nature Catalysis, 6(12), 1228-1240.

20-Dec-2023

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

More here:
First step towards synthetic CO2 fixation in living cells - EurekAlert

AI generates proteins with exceptional binding strength – ASBMB Today

A new studyin Nature reports an AI-driven advance in biotechnology with implications for drug development, disease detection, and environmental monitoring. Scientists at the Institute for Protein Design at the University of Washington School of Medicine used software to create protein molecules that bind with exceptionally high affinity and specificity to a variety of challenging biomarkers, including human hormones. Notably, the scientists achieved the highest interaction strength ever reported between a computer-generated biomolecule and its target.

Ian Haydon, UW Medicine Institute for Protein Design

Susana Vasquez-Torres in a UW Medicine Institute for Protein Design laboratory, where she is working to develop new proteins with high-binding affinity and specificity to a variety of challenging biomarkers.

Senior author David Baker, professor of biochemistry at UW Medicine, Howard Hughes Medical Institute investigator, and recipient of the 2023 Frontiers of Knowledge Award in Biology and Biomedicine, emphasized the potential impact: "The ability to generate novel proteins with such high binding affinity and specificity opens up a world of possibilities, from new disease treatments to advanced diagnostics."

Ian Haydon/UW Medicine Institute for Protein Design

A new protein designed using deep-learning methods. In this case, RFdiffusion generates a binding protein.

The team, led by Baker Lab members Susana Vazquez-Torres, Preetham Venkatesh, and Phil Leung, set out to create proteins that could bind to glucagon, neuropeptide Y, parathyroid hormone, and other helical peptide targets. Such molecules, crucial in biological systems, are especially difficult for drugs and diagnostic tools to recognize because they often lack stable molecular structures. Antibodies can be used to detect some of these medically relevant targets but are often costly to produce and have limited shelf lives.

"There are many diseases that are difficult to treat today simply because it is so challenging to detect certain molecules in the body. As tools for diagnosis, designed proteins may offer a more cost-effective alternative to antibodies," explained Venkatesh.

The study introduces a novel protein design approach that uses advanced deep-learning methods. The researchers present a new way of using RFdiffusion, a generative model for creating new protein shapes, in conjunction with the sequence-design tool ProteinMPNN. Developed in the Baker Lab, these programs allow scientists to create functional proteins more efficiently than ever before. By combining these tools in new ways, the team generated binding proteins by using limited target information, such as a peptide's amino acid sequence alone. The broad implications of this "build to fit" approach suggest a new era in biotechnology in which AI-generated proteins can be used to detect complex molecules relevant to human health and the environment.

Ian Haydon/UW Medicine Institute for Protein Design

An AI-designed protein in detail from the UW Medicine Institute for Protein Design.

"We're witnessing an exciting era in protein design, where advanced artificial intelligence tools, like the ones featured in our study, are accelerating the improvement of protein activity. This breakthrough is set to redefine the landscape of biotechnology," noted Vazquez-Torres.

In collaboration with the Joseph Rogers Lab at the University of Copenhagen and the Andrew Hoofnagle Lab at UW Medicine, the team conducted laboratory tests to validate their biodesign methods. Mass spectrometry was used to detect designed proteins that bind to low-concentration peptides in human serum, thereby demonstrating the potential for sensitive and accurate disease diagnostics. Additionally, the proteins were found to retain their target binding abilities despite harsh conditions including high heat, a crucial attribute for real-world application. Further showcasing the method's potential, the researchers integrated a high-affinity parathyroid hormone binder into a biosensor system and achieved a 21-fold increase in bioluminescence signal in samples that contained the target hormone. This integration into a diagnostic device highlights the immediate practical applications of AI-generated proteins.

The study, which illustrates the confluence of biotechnology and artificial intelligence and sets a new precedent in both fields, appears in Nature with the title De novo design of high-affinity binders of bioactive helical peptides.

(This article was produced by the University of Washington School of Medicine/UW Medicine.)

Read the original here:
AI generates proteins with exceptional binding strength - ASBMB Today

USM Chemistry (Biochemistry Emphasis) Degree Earns ASBMB Reaccreditation – The University of Southern Mississippi

Wed, 01/31/2024 - 01:21pm | By: Ivonne Kawas

The University of Southern Mississippis (USM) B.S. degree in Chemistry (Biochemistry emphasis) has earned reaccreditation by the leading agency in the field of life sciences the American Society for Biochemistry and Molecular Biology (ASBMB).

This accreditation was obtained for the first time in 2017. Obtaining ASBMB accreditation, a national outcomes-based evaluation, ensures programs in the field meet the highest standards of academic excellence. USMs chemistry degree program is housed in the School of Mathematics and Natural Sciences (MANS),

Accreditation by ASBMB is a testament to the quality and content of our biochemistry curriculum, as well as to the knowledge and skills learned by our students as they begin to seek careers or further their studies at the graduate or professional levels, said Dr. Chris Winstead, dean of the College of Arts and Sciences. I appreciate the effort of the faculty in seeking this accreditation. This shows their dedication to providing the best preparation possible for our Southern Miss students, an education that is well-aligned with national standards and prepares them for their next steps.

Dr. Vijay Rangachari, professor of chemistry and biochemistry, emphasizes one of the direct accreditation benefits for students.

ASBMB accreditation inherently enhances the value of the students degree, allowing them to include on their resume that they graduated from an ASBMB-accredited program. Furthermore, upon degree completion, they can demonstrate competitiveness on a national scale by obtaining ASBMB certification.

Dr. Rangachari also highlights one of the strengths of the program, integral to both student success and ASBMB accreditation: the hands-on research opportunities provided in the laboratory.

To meet accreditation requirements, the curricula must include over 400 hours of hands-on laboratory experience. Therefore, students get an advantage in advancing their careers.

Students like Landon Lee, a native of Hattiesburg, Miss. who is pursuing the biochemistry emphasis, actively participate in cutting-edge research projects in the lab, alongside graduate students and faculty mentors.

Joining a research lab has significantly enriched my educational experience, as Ive been able to acquire skills related to academic research, project management, and creative thinking, said Lee. With the support and guidance from both the graduate students in my lab and Dr. Rangachari, my faculty mentor, it has become more than just a platform for applying classroom concepts; it has provided me a community that fosters my personal and academic development.

After completing his bachelors degree, Lee plans to further his studies: As I complete my degree, I intend to pursue a Ph.D. in neuroscience. My coursework has undoubtedly laid a strong foundation in physics, chemistry, and mathematics, enabling me to demonstrate key strengths as I strive toward this goal.

Dr. Theofanis Kitsopoulos, director in the School of MANS, reflects on the programs successful and highly valued alumni base, as it opens doors to diverse industries.

Our curriculum is carefully crafted to equip students not only with a strong theoretical foundation but also with practical skills highly valued in the job market, said Dr. Kitsopoulos. Several of our alumni choose to pursue advanced degrees in prestigious graduate programs in medical, dental, pharmaceutical, and other professional schools. They go on to succeed in diverse industries such as research and development, healthcare, environmental consulting, forensic science, and entrepreneurship. Some thrive as quality control and analytical chemists, while others pursue fulfilling paths as middle and high school science and chemistry teachers.

Learn more about the B.S. degree in Chemistry (Biochemistry emphasis).

Continue reading here:
USM Chemistry (Biochemistry Emphasis) Degree Earns ASBMB Reaccreditation - The University of Southern Mississippi

Biochemistry: Definition And Explanation – University of the People

Biochemistry is exciting and fascinating science, and this article will tell you everything youve been wanting to know about the field. Well give you the full biochemistry definition: the basics, the history, as well as the promising degrees and careers you can expect in the biochemists laboratory and beyond.

Biochemistry, or biological chemistry, is the branch of science that studies chemical and physicochemical processes within living organisms.

Source: Pexels

As a combination of biology and chemistry, biochemistry studies the chemical substances and processes which occur within the biology of the body or any living organisms.

Biochemists study large molecules such as carbohydrates and proteins in relation to metabolism and other important processes within the body. Other molecules that biochemists may study include enzymes and DNA. These types of molecules are important for understanding the complex processes which occur in all living organisms.

The term biochemistry was created by Carl Neuberg, a German chemist, in 1902. But the study itself has been around for over 400 years, essentially since the invention of the microscope in 1665 by Robert Hooke. The microscope made it possible to study cells.

In 1674, Anton van Leeuwenhoek was the first to observe live plant cells under the microscope, which opened up many more possibilities than the dead cells which were being observed up until then. Live cells allowed scientists to observe chemical processes that occurred within and between them.

In the 18th century, a notable discovery in the field was made by the French scientist, Antoine Lavoisier, who proposed the concept of photosynthesis, a process in which plants convert water, sunlight, and carbon dioxide into their nutrients. Lavoisier was also the first person to study cell respiration, which is the process of making the energy molecule in the cells mitochondria.

In the 20th century, DNA was acknowledged as the genetic material which made up the cell. This was established by James Watson and Francis Crick based on the research work of Rosalind Franklin.

Most recently, new technology continues to advance scientific studies in areas such as recombinant DNA, gene splicing, radioisotopic labeling, and electron microscopy.

A career in biochemistry is recommended for those who enjoy research, as it is generally a career in laboratory science. Most careers in the field require at least a bachelors degree, such as a position as a laboratory technician. Other positions, such as laboratory managers or principal investigators of research, will require a masters degree or a Ph.D.

Laboratory technicians engage in bench work and help perform experiments in the lab under the instruction of the principal investigators. Technicians need a bachelors degree in order to be qualified, but more education and research will allow for more independence in the lab.

Lab managers carry more responsibility in the laboratory and may conduct independent research under the guidance of the principal investigator.

Though a masters degree in the field will require an emphasis on research, a Ph.D. prepares biochemists for a career in independent research, principal investigators of research in laboratories, and lecturers in university.

There are also many industry positions available to biochemists. Biochemists may also work in governmental labs or for companies in agriculture, pharmaceuticals, public health, or biotechnology. Some biochemists may also work in services such as toxicology and forensics.

Source: Pexels

As one may imagine, a contender for biochemistry needs to have a good understanding of both biology and chemistry. Some universities may offer a specific biochemistry track, or students can begin their education by taking a bachelors degree in either biology or chemistry, with a minor in the other.

Biochemists also need to have a good grasp of mathematics and statistics in order to conduct research. As students advance in their studies, they will begin to hone in on their particular interests.

Similar studies include health sciences, which offer courses in biology, anatomy, biostatistics, and disease prevention. Universities such as the University of the People (UoPeople) offer associates and bachelors degrees in health science completely online and tuition-free. The university also offers potential certificate programs in health science that can give ones career the right boost.

As weve seen, the biochemistry definition includes a rich history and an exciting future for further discoveries. Since the invention of the microscope, biochemists have been investigating the complex, hidden world of cells and molecules.

Biochemistry is an exciting and constantly evolving field of science with an emphasis on research and laboratory technology. Different levels of education open up many opportunities for working in the field. If you have a passion for this science, then biochemistry may be a meaningful career choice for you.

Link:
Biochemistry: Definition And Explanation - University of the People

Automated Biochemistry Analyzers Industry is Expected to Reach $8 Billion by 2028 -Abbott, Danaher, Hitachi, Roche, Siemens, Thermo Fisher Scientific…

A market study Global examines the performance of the Automated Biochemistry Analyzers 2022. It encloses an in-depth analysis of the Automated Biochemistry Analyzers state and the competitive landscape globally. The Global Automated Biochemistry Analyzers can be obtained through the market details such as growth drivers, latest developments, Automated Biochemistry Analyzers business strategies, regional study, and future market status. The report also covers information including Plastic Additive industry latest opportunities and challenges along with the historical and Automated Biochemistry Analyzers future trends. It focuses on the Automated Biochemistry Analyzers dynamics that is constantly changing due to the technological advancements and socio-economic status.Pivotal players studied in the Automated Biochemistry Analyzers report:

Abbott, Danaher, Hitachi, Roche, Siemens, Thermo Fisher Scientific

Get free copy of the Automated Biochemistry Analyzers report 2022: https://www.mraccuracyreports.com/report-sample/550938

Recent market study Automated Biochemistry Analyzers analyses the crucial factors of the Automated Biochemistry Analyzers based on present industry situations, market demands, business strategies adopted by Automated Biochemistry Analyzers players and their growth scenario. This report isolates the Automated Biochemistry Analyzers based on the key players, Type, Application and Regions. First of all, Automated Biochemistry Analyzers report will offer deep knowledge of company profile, its basic products and specification, generated revenue, production cost, whom to contact. The report covers forecast and analysis of Automated Biochemistry Analyzers on global and regional level.

COVID-19 Impact Analysis:

In this report, the pre- and post-COVID impact on the market growth and development is well depicted for better understanding of the Automated Biochemistry Analyzers based on the financial and industrial analysis. The COVID epidemic has affected a number of Automated Biochemistry Analyzers is no challenge. However, the dominating players of the Global Automated Biochemistry Analyzers are adamant to adopt new strategies and look for new funding resources to overcome the rising obstacles in the market growth.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.mraccuracyreports.com/reportdetails/reportview/550938

Product types uploaded in the Automated Biochemistry Analyzers are:

Stationary Biochemistry Analyzers, Portable Biochemistry Analyzers

Key applications of this report are:

Hospital and Diagnostic Laboratories, Home Care, and Academic, Research Institutes

Geographic region of the Automated Biochemistry Analyzers includes:

North America Automated Biochemistry Analyzers(United States, North American country and Mexico),Europe Market(Germany, Plastic Additive France Market, UK, Russia and Italy),Asia-Pacific market (China, Plastic Additive Japan and Korea market, Asian nation and Southeast Asia),South America Plastic Additive Regions inludes(Brazil, Argentina, Republic of Colombia etc.),Plastic Additive Africa (Saudi Arabian Peninsula, UAE, Egypt, Nigeria and South Africa)

The Plastic Additive report provides the past, present and future Plastic Additive industry Size, trends and the forecast information related to the expected Plastic Additive sales revenue, growth, Plastic Additive demand and supply scenario. Furthermore, the opportunities and the threats to the development of Automated Biochemistry Analyzers forecast period from 2022 to 2029.

Please click here today to buy full report @ https://www.mraccuracyreports.com/checkout/550938

Further, the Plastic Additive report gives information on the company profile, market share and contact details along with value chain analysis of Plastic Additive industry, Plastic Additive industry rules and methodologies, circumstances driving the growth of the Automated Biochemistry Analyzers and compulsion blocking the growth. Automated Biochemistry Analyzers development scope and various business strategies are also mentioned in this report.

Call Us - UK +44 7452119323USA +1 8045001224Email us - sales@mraccuracyreports.com30 Crawley Lane, West Sussex, RH10 7EG, United Kingdom3351 Green Turtle Rd, Regina, SK S4V 3N6, Canada

MR Accuracy Reports is a Market Research and consulting company that accomplishes requirement of research agencies,small, medium and large corporations, global business leaders, government organizations, SME's, Individual & Start-ups, top management consulting firms.

This release was published on openPR.

Here is the original post:
Automated Biochemistry Analyzers Industry is Expected to Reach $8 Billion by 2028 -Abbott, Danaher, Hitachi, Roche, Siemens, Thermo Fisher Scientific...

Maroon and White royalty: MSU unveils 2022 Homecoming Court – Mississippi State University

Contact: Carl Smith

Mississippi State Universitys 2022 Homecoming Court includes (left to right) freshman Maid Natalie Robertson of Hamilton, Alabama; sophomore Maid Sydiah Ervin of Pinson, Alabama; junior Maid Allie Grace Bell of Madison; senior Maid Olivia Sinclair Russell of Southaven; Mr. MSU Davis Helton of Amory; Homecoming Queen Raegan Rushing of Biloxi; Homecoming King Hayden Foil of Gautier; Miss MSU Avery Braddock of Loveland, Ohio; senior Maid Sara Matheson of Collierville, Tennessee; junior Maid Lucie LeBlanc of Brookhaven; sophomore Maid Khaoula Kamal of Tupelo; and freshman Maid Nya Nobles of Shubuta. (Photo by Grace Cockrell)

STARKVILLE, Miss.Mississippi State students have chosen a new group of Bulldogs to represent the school in its 2022 Homecoming Court.

Hayden Foil of Gautier and Raegan Rushing of Biloxi are king and queen of this years homecoming, an event-filled week Oct. 2-8 culminating with MSUs football game against the University of Arkansas at 11 a.m. Saturday [Oct. 8]. Foil is a senior animal and dairy science/ pre-veterinary major, and Rushing is a senior industrial engineering major.

Homecoming King Hayden Foil (left) of Gautier and Homecoming Queen Raegan Rushing of Biloxi. (Photo by Grace Cockrell)

This years Miss MSU is Avery Braddock of Loveland, Ohio, and Mr. MSU is Davis Helton of Amory. Braddock is a senior communication/public relations major, and Helton is a senior biochemistry/pre-dental major.

Miss MSU Avery Braddock (left) of Loveland, Ohio, and Mr. MSU is Davis Helton of Amory. (Photo by Grace Cockrell)

The homecoming court, including eight class maids, will be presented formally during next Saturdays halftime at Davis Wade Stadium. For more information on MSU gameday activities, visit HailState.com/gameday.

Each undergraduate class is represented by two maids:

SENIORSara Matheson, a biochemistry/pre-medicine major from Collierville, Tennessee, and Olivia Sinclair Russell, a mechanical engineering major from Southaven.

JUNIORAllie Grace Bell, an accounting major from Madison, and Lucie LeBlanc, a chemical engineering major from Brookhaven.

SOPHOMORESydiah Ervin, a biomedical engineering major from Pinson, Alabama, and Khaoula Kamal, a biomedical engineering major from Tupelo.

FRESHMANNya Nobles, a biochemistry/pre-dental major from Shubuta, and Natalie Robertson, a communication/broadcast and digital journalism major from Hamilton, Alabama.

For more on 2022 homecoming week activities, follow the MSU Student Association on Facebook @MSUStudentAssociation, as well as @MSU_SA on Twitter and Instagram.

MSU is Mississippis leading university, available online at http://www.msstate.edu.

See more here:
Maroon and White royalty: MSU unveils 2022 Homecoming Court - Mississippi State University

Shining lights on the cell – ASBMB Today

The cellular machinery is a remarkable system that is able to regulate myriad life processes with exquisite specificity by responding to a variety of environmental cues. This essential regulation is achieved through a network of highly dynamic signaling molecules that are regulated both spatially and temporally.

Inspired by natures fluorescent proteins and photosensors, biochemists have made tremendous advances toward developing new classes of genetically encoded protein tools to detect and control signaling activities with high spatiotemporal precision. With these new tools, new kinds of biochemistry, biology and cell biology are being discovered on a regular basis.

For the American Society for Biochemistry and Molecular Biology annual meeting, Discover BMB, in Seattle in March, we have assembled symposia featuring some of the top experts in these diverse fields who will discuss new tools for manipulating and visualizing the activity of enzymes and other classes of protein activity in living cells across a range of settings. As an example of the impact of these tools, we will highlight the emerging field of liquidliquid phase separation as an organizing principle of cell signaling uniquely identified by advances in our ability to probe and control biomolecules in vitro and in cells.

Keywords: Optogenetics, fluorescent biosensors, protein engineering, phase separation.

Who should attend: Biochemists, cell biologists and protein engineers interested in novel protein-based tools to observe and control cellular behavior as well as new concepts in cellular organization that have emerged from use of these reagents.

Theme song: Blinding Lights by The Weeknd.

This session is powered by high-quality photons from the UV to the infrared.

Toolkit for native biochemistry: Sensors, actuators and computational toolsKevin H. Gardner (chair),City University of New York Advanced Science Research CenterKlaus Hahn,University of North Carolina at Chapel HillSabrina Spencer,University of Colorado BoulderDavid van Valen,California Institute of Technology

Spatiotemporal control of cellular signalingJin Zhang (chair),University of California, San DiegoMark von Zastrow,University of California, San FranciscoLukasz Bugaj,University of PennsylvaniaAnton Bennett,Yale University

Liquidliquid phase separation as a signaling paradigmChristine Mayr (chair),Memorial Sloan Kettering Cancer CenterZhijian "James" Chen,University of Texas Southwestern Medical CenterSarah Veatch,University of MichiganShana ElbaumGarfinkle,City University of New York Advanced Science Research Center

Read more from the original source:
Shining lights on the cell - ASBMB Today

IARI-ICAR Recruitment 2022: Check Post, Qualification and Other Details Here – StudyCafe

IARI-ICAR Recruitment 2022: Check Post, Qualification and Other Details Here

IARI-ICAR Recruitment 2022: Indian Agricultural Research Institute (ICAR) is inviting eligible candidates to attend the Online Interview for Unreserved Temporary Posts of Six SRFs under the ongoing project funded by the National Agriculture Science Fund, Indian Council of Agricultural Research, Ministry of Agriculture and Farmers Welfare, Government of India. Interested candidates should review the job description and apply using the link provided in the official notification. The applicant should have a Masters degree in relevant subjects (Plant Biotechnology/ Plant Physiology/ Plant Biochemistry/Life sciences/ Microbiology) with 4 years/ 5 years of Bachelors degree will be given preference. The last date for receipt of the Biodata is 20th October 2022.

Candidates are requested to apply for the job post before the deadline. No application shall be entertained after the stipulated time/ date. Incomplete applications and applications received after the specified time/ date shall be REJECTED. All the details regarding this job post are given in this article such as IARI-ICAR Recruitment 2022 official Notification, Age Limit, Eligibility Criteria, Pay Salary & much more.

1. The applicant should have a Masters degree in relevant subjects (Plant Biotechnology/ Plant Physiology/ Plant Biochemistry/Life sciences/ Microbiology) with 4 years/ 5 years of Bachelors degree will be given preference.

2. Desirable qualifications: Agrobacterium mediated genetic transformation of rice/soybean/mustard, genome editing of plants, molecular cloning, Molecular analysis of transgenic plants and other basic molecular techniques

Selected Candidates will be getting the salary amount of Rs.31000 + HRA per month for 1st and 2nd years and Rs.35000 + HRA per month for 3rd year.

Maximum 35 years for men for SRF positions. For women/SC/ST/OBC, age relaxation of 5 years will be given as per Govt. of India/ICAR rules.

Step 1: Go to the IARI-ICAR official website.

Step 2: Search for the IARI-ICAR Recruitment 2022 Notification here.

Step 3: Read all of the information in the notification.

Step 4: Apply and submit the application form in accordance with the mode of application specified in the official notification.

NOTE: Candidates may send their biodata with self-attested scanned copies of degree certificates, and mark sheets of 10, 12, UG and PG to [emailprotected] The last date for receipt of the Biodata is 20th October 2022.

To Read Official Notification Click Here

Disclaimer: The Recruitment Information provided above is for informational purposes only. The above Recruitment Information has been taken from the official site of the Organisation. We do not provide any Recruitment guarantee. Recruitment is to be done as per the official recruitment process of the company or organization posted the recruitment Vacancy. We dont charge any fee for providing this Job Information. Neither the Author nor Studycafe and its Affiliates accepts any liabilities for any loss or damage of any kind arising out of any information in this article nor for any actions taken in reliance thereon.

Excerpt from:
IARI-ICAR Recruitment 2022: Check Post, Qualification and Other Details Here - StudyCafe

A celebration: Fiesta Latina shares the sounds and tastes of Latino culture with Columbus – The Republic

Mike Wolanin | The Republic A piata hangs from a booth during Fiesta Latina in downtown Columbus, Ind., Saturday, Oct. 1, 2022.

Fiesta Latina had a picture-perfect afternoon and evening for the return of the annual festival, which brought thousands of visitors to downtown Columbus for the tastes and sounds of the Latino community.

The free admission gathering stretched from noon to 10 p.m. overall celebrating the rich culture of Latin America; showcasing Latino musicians, dancers, artisans, and chefs from around the region, according to organizers promotional materials.

Proceeds from the event go to help Su Casa serve its Latino community, so that all Latinos feel welcome and safe, with equal access to opportunities that encourage a sense of pride and belonging, according to the website at sucasaindiana.org/fiesta-latina/.

Among the performers was Sabada, a group with Brazilian backgrounds. Ballet Folklorico Mosaicos performed and music took over the evening festivities, including a Mariachi band and then music from a DJ.

Our goal is to highlight the amazing culture that Latinos contribute to a vibrant community, said Luz Elena Michel, who helped organize the event and is among the organizers of TuFuturo, the Latino education group.

In a highlighted event, TuFuturo, an initiative of the Community Education Coalition, is organizing a Latino conference called Es Posible on Friday.

Its purpose is for students to visualize their next step upon finishing high school, learn about career options and many other aspects to consider to futher their education.

The conference is directed toward Hispanic students in grades seven through 10.

Keynote speakers will be Paola Ariza-Storch and Heriberto Acevedo. Ariza-Storch is a rising senior at Butler University studying biochemistry and neuroscience with the hopes of becoming a physician.

Paola is a Columbus local, who graduated from Columbus East High School in 2019. Paola was born and raised on the island of Puerto Rico and completed undergraduate studies at the University of Puerto Rico, with a degree in chemical sciences. He worked as a science teacher for the seventh grade to high school and now works as a research and development scientist at Eli Lilly.

For more information, or to register online, contact Es Posble on Instagram, Facebook or TikTok at @TuFuturoLatino.

See the original post:
A celebration: Fiesta Latina shares the sounds and tastes of Latino culture with Columbus - The Republic

A Cross-Sectional Study of Various Imaging and Biochemical Biomarkers | OPTH – Dove Medical Press

Introduction

Diabetes is a metabolic disorder affecting 463 million people globally and 77 million people in India. When ophthalmic manifestations are considered, DR is taking center stage today. DR is one of the leading causes of blindness worldwide in working adult age groups.1

DR naturally progresses from non-proliferative abnormalities to proliferative diabetic retinopathy (PDR), characterized by neovascularization involving disc (NVD) or neovascularization elsewhere (NVE). The leading cause of vision loss in DR patients is Diabetic Macular Edema (DME). DME is characterized by retinal thickening and edema, which can develop in all stages of retinopathy.2

Many studies and clinical trials have confirmed significant risk factors for DME, such as hyperglycemia, dyslipidemia, hypertension, smoking, and nephropathy.2 There are many biomarkers to assess these risk factors for DR and DME. It can be clinical (general and ocular), imaging, biochemical, and molecular.3

One of the imaging modalities used to assess DR and DME is OCT. It is a non-invasive, non-contact method for assessment of macular edema and each feature observed in OCT acts as an imaging biomarker. The biochemical biomarkers considered are glycosylated hemoglobin (HbA1c), total cholesterol, serum low-density lipoprotein (LDL), serum high-density lipoprotein (HDL), total triglycerides, serum creatinine, serum urea and microalbuminuria.4

The relationship between different biomarkers and stages of DR and DME will be necessary for optimal clinical management and new clinical strategies to prevent vision loss. However, no studies have established a strong association between these biomarkers in different stages of DR. In our study, we compared these biomarkers for DME in various stages of DR and their association with each stage of DR.

It is a cross-sectional observational study conducted at the Department of Ophthalmology of AIIMS, Raipur, between 1 May 2020 and 31 October 2021. The study was approved by the Institutional Ethics Committee of All-India Institute of Medical Sciences (AIIMS) Raipur, India, and the study was carried out as per the tenets of the Declaration of Helsinki (IEC Approval Number: 1026). Written informed consent was taken from all the patients to use the data for research purposes. All patients of type 2 DM with DME with ages ranging from 30 to 70 years with Central Subfield Thickness (CST) on CIRRUS 500 SD-OCT [Carl Zeiss Meditec, Jena, Germany] >250m were included in the study. We included one eye for each patient. In cases of bilateral DME, we included the eye with higher CST on OCT. Patients with a history of having undergone scattered retinal photocoagulation (PRP)/focal laser, history of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) or steroids, YAG capsulotomy within 3 months in the same eye, present or past evidence of uveitis, cataract surgery within 6 months, eye trauma and patients with media opacity like cataract causing hindrance for fundus/OCT examination were excluded from the study. Complete ophthalmic examination was done under slit-lamp biomicroscopy and indirect ophthalmoscope, and patients were graded according to the International Clinical Disease Severity Scale for DR and DME.5 We divided the patients into two major study groups: Group A DME with NPDR and Group B DME with PDR. Group A was further subdivided into three categories based on different stages of NPDR: Group A (1) DME with mild NPDR, Group A (2) DME with moderate NPDR, and Group A (3) DME with severe NPDR. OCT was done to quantify DME, and a horizontal raster scan of 1212mm length was taken through the foveal centre. OCT morphological patterns were assessed by a single vitreoretinal specialist, including central subfield thickness (CST), cystoid macular edema (CME), diffuse retinal thickening (DRT), hyperreflective retinal foci, subretinal fluid (SRF), and epiretinal membrane (ERM). Blood and urine investigations were done on the same day. Those being HbA1c, serum LDL, serum HDL, serum triglycerides, total cholesterol, serum creatinine, serum urea, and microalbuminuria. The primary outcome measure was to compare imaging and biochemical biomarkers in type 2 diabetic patients with DME in different stages of diabetic retinopathy.

Statistical analysis was carried out using statistical packages for IBM SPSS vs 22 for Windows. Continuous and categorical variables were expressed as mean SD and percentages, respectively. Two-sided p values were considered statistically significant at p<0.05. Chi-square test was applied for comparison of categorical variables and one-way ANOVA test for continuous variables.

We included 100 eyes of 100 patients with type 2 DM with DR and DME in the study. The overall mean age of the study population was 54.849.87 years. The mean age of patients in Group A was 55.45 9.88 years, while the mean age of those in Group B was 53.34 9.88 years. The two groups did not show a significant difference in age distribution (P=0.336). Male preponderance was observed amongst the study population (76%). The mean duration of diabetes in Group A was 10.59 5.21 years, and that in Group B was 9.82 5.72 years, found to be very similar among the two study groups (p=0.52).

Out of 100 patients, 1 (1%) was diagnosed with DME with mild NPDR, 44 (44%) with DME with moderate NPDR, 29 (29%) with DME with severe NPDR, and 29 (29%) with DME with PDR. As Group A (1) had only one patient, we did not include it in the calculation. Mean CST was high in all groups, and the analysis of CST in the study groups was done by one-way ANOVA test, but we did not find any significant difference between the study groups (p= 0.494; p>0.05). The commonest OCT biomarker was CME amongst all patients of both groups, which was 69%, followed by SRF (64%), HRF (60%), DRT (50%), and less common was ERM (18%). We used the Chi-square test to compare these biomarkers between various groups. There was no significant difference found (p>0.05) for CME, HRF, and SRF, but the presence of DRT and ERM was more in Group B and found to be significant (p=0.04) (Table 1).

Table 1 Comparison of Various OCT Biomarkers

One-way ANOVA test was applied for analysis of all continuous variables. The mean fasting and post-prandial blood sugar levels were high in both groups, but the difference was not statistically significant (FBS, p=0.727; PPBS, p=0.444).

The mean HbA1c was more than 7% for all groups and slightly high for Group B, but the difference was insignificant (p=0.090). The mean serum LDL level, mean serum triglyceride level, mean microalbuminuria level, and mean serum creatinine level were compared between groups, but we did not find any significant association between these factors and DR. We found that only mean serum urea level was high in Group B and a significant difference was found amongst the groups (p=0.027; p<0.05) (Table 2).

Table 2 Comparison of Biochemical Biomarkers

DR can be defined as prolonged hyperglycemia leading to retinal microvascular damage. This internally leads to DME, a common cause of vision loss and visual disability worldwide.6

DME is a preventable cause of vision loss; elucidating and preventing the risk factors of DME can go a long way in reducing morbidity in diabetics. Many studies have been done to elicit the risk factors and biomarkers for DME. Still, no studies have compared these imaging and biochemical biomarkers with various stages of DR with DME and associated their relation with the severity of the disease. This study might add to the literature and bridge the gap, which will help in better management.

The mean age in both the groups of the present study signifies middle age group is usually affected by DR and DME, similar to other studies.7,8 Male preponderance was observed in our study (76%). The prolonged duration of diabetes is a known risk factor for DR and DME. We observed that both groups had an almost similar mean duration of diabetes (10 years or more), indicating that longer duration was a factor responsible for the development of DR and DME.9 Duration of disease is a significant risk factor for the development of DR but not a marker for severity of the disease.

The advent of OCT has been an essential tool in assessing the CST and also monitoring the patients with DME for progression of the disease.10

In the present study, the mean CST was high in Group A (3) (436.23140.58 m) and low in the Group B (397.4895.41 m), but there was no remarkable difference among the study groups (p=0.494). In contrast, a study done by Yassin et al concluded that CST had a positive correlation with the severity of the disease when different stages of DR were taken into consideration, with high-risk PDR (P=0.050) and severe NPDR (P=0.021) being statistically significant.11 In the present study, cystoid pattern was the most common morphological pattern, and CME was almost equally present in all the study groups, similar to Acan et al.12 DRT is the most common pattern according to many studies.11

Yassin et al also concluded that DRT is associated with significantly good visual acuity.11 However, in contrast, DRT was increasingly present (69%) in the severe stage of DR (DME with PDR) in the present study. Ghosh et al concluded that there is a correlation between serum creatinine and albuminuria with that of DME, primarily serous type strongly associated with albuminuria.13 In our study, SRF was present in more than 50% of the patients in each study group but not significantly different in each study group (p=0.329).

An infrequent OCT finding in the present study was ERM. Still, we observed it in a more significant number of patients belonging to Group B (31.0%). Knyazer et al found a significant association between ERM to age, cataract surgery, and diabetic retinopathy.14 Knyazer et al also reported a prevalence of ERM at 6.5% in type 2 diabetes mellitus, and Mitchell et al reported a prevalence of 11% in patients with DR.

While Ng et al reported a high prevalence of ERM that is 33.3% in both types of DM, there is a paucity of information in the literature regarding the correlation between the presence of ERM and stages of DR.15,16

In our study, the blood glucose levels were, in general, raised more than the normal range amongst all the study groups indicating that deranged blood glucose levels as one of the risk factors for the development of DME in DR patients.17 HbA1c levels best reflect the glycaemic control in DR patients. It is well-established now that tight blood glucose control early in the course of diabetes is beneficial in the protection against DR. This knowledge was provided by the randomized controlled intervention trial in type 1 diabetes patients by the Diabetes Control and complications Trial (DCCT) and in type 2 diabetes patients by the United Kingdom Prospective Diabetes Study (UKPDS).18,19 Asensio-Sanchez et al, in their study, reported that increased levels of HbA1c were significantly associated with CSME, with an increase of 2.4 with every 1% elevation in HbA1c.2 In the present study, HbA1c was deranged in all patients with various stages of DR with DME, although it was slightly high in Group B (mean HbA1c-8.872.19%); in comparison, we did not find it significant (p=0.090).20

Raman et al, in their study SN DREAM, and Benarous et al reported a significant correlation between high cholesterol levels and severity of DR and CSME.7,21 In the present study, the mean serum LDL level difference was not substantial, but serum LDL levels were observed to be more deranged in Group B patients (mean=350.931128.15 mg/dL). In our study, we found serum triglyceride levels and serum cholesterol levels were deranged amongst all the study groups suggesting higher levels of serum triglyceride and serum cholesterol may be involved in the development of DME, and levels were slightly elevated in Group B patients. Still, no significant association was found between these factors and DR (p<0.05). Not many studies have been done to elicit the correlation between serum urea and different stages of diabetic retinopathy in DME patients. The comparison of mean serum urea levels was made, and a significant difference was found amongst the groups (p=0.027); on further evaluation, we found high serum urea levels present amongst the patients in Group B (mean=64.2765.52 mg/dL), indicating its relation to the severity of disease but needs more studies to establish more decisive conclusion with larger sample size. Similarly, the mean microalbuminuria level in Group B patients was found it be high (mean=337.83412.87 g/min), but when a comparison was made by one-way ANOVA test, it was not significant (p>0.05).

Zander et al reported microalbuminuria as one of the risk factors associated with DME and DR.22 In this study, the mean microalbuminuria was found to be at an increasing level in Group B patients stipulating that microalbuminuria can be one of the risk factors in the development of DME and severity of disease but cannot be concluded in our study due to poor sample size.

Koo et al reported that SRF in OCT was significantly associated with an increase in levels of microalbuminuria as compared to other OCT patterns.23 Acan et al reported that microalbuminuria was considerably higher in patients with DRT patterns in OCT (61.9%) compared to SRF (50.0%) and CME patterns (25.0%).12 In our study, we could not elicit any association between microalbuminuria and specific pattern of OCT, especially SRF.

Imaging biomarkers such as patterns of OCT findings, those being DRT and ERM have the potential to be the indicators for assessing the severity of the disease, but significant conclusions could not be drawn due to the lack of sufficient sample. Likewise, biochemical biomarkers such as serum urea and microalbuminuria were found to be deranged in severe stages of the disease, which needs further evaluation to be concluded as indicators of disease severity.

The authors report no financial interest or conflicts of interest in this work.

1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.

2. Asensio-Snchez VM, Gmez-Ramrez V, Morales-Gmez I, et al. Clinically significant diabetic macular edema: systemic risk factors. Arch Soc Esp Oftalmol. 2008;83(3):173176.

3. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S84S87. doi:10.2337/diacare.27.2007.s84

4. Jenkins AJ, Joglekar MV, Hardikar AA, et al. Biomarkers in diabetic retinopathy. Rev Diabet Stud. 2015;12(12):159195. doi:10.1900/RDS.2015.12.159

5. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):16771682. doi:10.1016/S0161-6420(03)00475-5

6. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):17961806.

7. Raman R, Rani PK, Kulothungan V, Rachepalle SR, Kumaramanickavel G, Sharma T. Influence of serum lipids on clinically significant versus nonclinically significant macular edema: SN-DREAMS Report number 13. Ophthalmology. 2010;117(4):766772. doi:10.1016/j.ophtha.2009.09.005

8. Mukhtar A, Khan MS, Junejo M, Ishaq M, Akbar B. Effect of pan retinal photocoagulation on central macular thickness and visual acuity in proliferative diabetic retinopathy. Pak J Med Sci. 2016;32(1):221224. doi:10.12669/pjms.321.8758

9. Ferris FL 3rd. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28 Suppl:452461. doi:10.1016/0039-6257(84)90227-3

10. Peng YJ, Tsai MJ. Impact of metabolic control on macular thickness in diabetic macular oedema. Diab Vasc Dis Res. 2018;15(2):165168. doi:10.1177/1479164117746023

11. Yassin SA, ALjohani SM, Alromaih AZ, Alrushood AA. Optical coherence tomography patterns of diabetic macular edema in a Saudi population. Clin Ophthalmol. 2019;13:707714. doi:10.2147/OPTH.S199713

12. Acan D, Karahan E, Kocak N, Kaynak S. Evaluation of systemic risk factors in different optical coherence tomographic patterns of diabetic macular edema. Int J Ophthalmol. 2018;11(7):12041209. doi:10.18240/ijo.2018.07.21

13. Ghosh S, Bansal P, Shejao H, Hegde R, Roy D, Biswas S. Correlation of morphological pattern of optical coherence tomography in diabetic macular edema with systemic risk factors in middle aged males. Int Ophthalmol. 2015;35(1):310. doi:10.1007/s10792-014-9922-z

14. Knyazer B, Schachter O, Plakht Y, et al. Epiretinal membrane in diabetes mellitus patients screened by nonmydriatic fundus camera. Can J Ophthalmol. 2016;51(1):4146. doi:10.1016/j.jcjo.2015.09.01

15. Mitchell P, Smith W, Chey T, Wang JJ, Chang A. Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. Ophthalmology. 1997;104(6):10331040. doi:10.1016/S0161-6420(97)30190-0

16. Ng CH, Cheung N, Wang JJ, et al. Prevalence and risk factors for epiretinal membranes in a multi-ethnic United States population. Ophthalmology. 2011;118(4):694699. doi:10.1016/j.ophtha.2010.08.009

17. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 1992;15(12):18751891. doi:10.2337/diacare.15.12.1875

18. Nathan DM. DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):916. doi:10.2337/dc13-2112

19. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643648. doi:10.1046/j.1365-2125.1999.00092

20. Vitale S, Maguire MG, Murphy RP, et al. Clinically significant macular edema in type I diabetes. Incidence and risk factors. Ophthalmology. 1995;102(8):11701176. doi:10.1016/s0161-6420(95)30894-9

21. Benarous R, Sasongko MB, Qureshi S, et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52(10):74647469. doi:10.1167/iovs.11-7598

22. Zander E, Herfurth S, Bohl B, et al. Maculopathy in patients with diabetes mellitus type 1 and type 2: associations with risk factors. Br J Ophthalmol. 2000;84(8):871876. doi:10.1136/bjo.84.8.871

23. Koo NK, Jin HC, Kim KS, Kim YC. Relationship between the morphology of diabetic macular edema and renal dysfunction in diabetes. Korean J Ophthalmol. 2013;27(2):98102. doi:10.3341/kjo.2013.27.2.98

See the original post here:
A Cross-Sectional Study of Various Imaging and Biochemical Biomarkers | OPTH - Dove Medical Press

Scope of Biochemistry in Pakistan | Jobs, Salary, And Career – The Academia Mag

Choosing a career is a tough task, especially when it comes to deciding which degree one wants to choose. It can be a tough decision, as we dont know what the future holds, or which career would be in high demand in the coming days. However, the field of biochemistry is always on the rise, and it opens a gateway to multiple job opportunities once you graduate with a degree in biochemistry. Students often wonder if the scope of biochemistry is good in Pakistan or if they will have a bright future with the qualification of biochemistry. Well, if you are interested and very much passionate about biochemistry but confused if this qualification has any scope in our country, then you have landed on the right page. Because in this article we will discuss everything related to biochemistry as to what is the scope of this qualification, the jobs, the salary, and what career opportunities it holds.

Read on!

Biochemistry is the chemistry of biological processes. This subject deals with all kinds of biological processes which involves chemical reactions like reproduction, metabolism, growth, etc. Biochemistry also includes the sciences of biophysical chemistry, neurochemistry, bioorganic, etc. Biochemistry helps individuals understand biology at a molecular level, it also offers a wide variety of techniques that are critical for conducting research in biomedical or agricultural fields. It has also made quite significant contributions towards understanding as well as finding the DNA structures.

Many students often ask this question while choosing a higher education degree because everyone wants a secure future with a great job. Well, one thing is for sure, there is a huge demand and scope in the field of biochemistry in Pakistan so the students wanting to pursue this degree can choose it in an instant. A graduate in biochemistry can easily find a good job whether in a private or a public sector. There are multiple fields in which a biochemist can easily get employment. In fact, biochemistry is a field where an individual can very quickly make a rewarding secure career.

The employment of biophysicists and biochemists is expected to grow by a whopping 15% in the coming years. After obtaining a degree in biochemistry, the graduates can easily get great work opportunities in a wide range of fields which includes hospitals, education sectors, agriculture, research organizations, food institutes, and much more. The demand for biochemistry has always been on the rise in Pakistan and it will continue to do so. Hence, biochemistry is a good career in Pakistan.

Read more: Scope of Food Science and Technology in Pakistan

As biochemistry is known to be used in a vast variety of fields which includes agriculture, pharmaceutical companies, research organizations, education sectors, etc. People who hold a degree in biochemistry can work in numerous places and fields. This may include:

The salary of biochemists varies from industry to private sector or public sector. It also depends on the qualifications and skill sets one has. But an average salary of a biochemistry graduate would be from approximately 50,000- 65,000 per month. However, the salary may raise with the passage of time and may go up to 75,000- 150,000 per month.

Good Luck!

Original post:
Scope of Biochemistry in Pakistan | Jobs, Salary, And Career - The Academia Mag

UCF Researchers Prove that COVID Disinfectant Works in Latest Research Paper – UCF

A team of UCF researchers have proven the efficacy of a nanomaterial-based disinfectant they developed to combat the spread of the COVID-19 virus. Through their experiments, they found that the disinfectant was able to kill several serious viruses including SARS and Zika. The results of their findings were recently published in ACS Applied Materials and Interfaces.

It is always a delight to have our research work featured in a reputed journal, said Udit Kumar, a doctoral student in the Department of Materials Science and Engineering (MSE) and the lead author of the journal article. Given the theme and possible impact of antiviral research in current times, our article will definitely aid our fight against global pandemics.

The paper outlines the most recent study from a multidisciplinary team of researchers that includes Sudipta Seal, the chair of the MSE department, and Griff Parks, a College of Medicine virologist and director of the Burnett School of Biomedical Sciences. They experimented with the nanomaterial yttrium silicate, which has antiviral properties that are activated by white light, such as sunlight or LED lights. As long as there is a continuous source of light, the antiviral properties regenerate, creating a self-cleaning surface disinfectant.

Yttrium silicate acts as a silent killer, with antiviral properties constantly recharged by the light, Kumar says. It is most effective in minimizing surface to the surface spread of many viruses.

Kumar says their test of yttrium silicate in white light disinfected surfaces with high viral loads in approximately 30 minutes. Additionally, the nanomaterial was able to combat the spread of other viruses including parainfluenza, vesicular stomatitis, rhinovirus, Zika and SARS.

This disinfectant technology is an important achievement for both engineering and health because we all were affected during the pandemic, Seal says. COVID is still ongoing and who knows what other illnesses are on the horizon.

Other UCF researchers, including College of Medicine postdoctoral researcher Candace Fox 16MS 19PhD, nanotechnology student Balaashwin Babu 20 and materials science and engineering student Erik Marcelo, are co-authors on the paper.

This publication is the culmination of timely insight by the investigators as to the importance of rapid development of broad-spectrum anti-microbials, as well as hard work in the lab to show the potency of our new materials, Parks says. This is an outstanding example of the power of cross-discipline research in this case, materials science and microbiology researchers from CECS and COM.

The research is funded by the U.S. National Science Foundations RAPID program.

Seal joined UCFs Department of Materials Science and Engineering and the Advanced Materials Processing Analysis Center, which is part of UCFsCollege of Engineering and Computer Science, in 1997. He has an appointment at theCollege of Medicineand is a member of UCFs prosthetics clusterBiionix. He is the former director of UCFs NanoScience Technology Center and Advanced Materials Processing Analysis Center. He received his doctorate in materials engineering with a minor in biochemistry from the University of Wisconsin and was a postdoctoral fellow at the Lawrence Berkeley National Laboratory at the University of California Berkeley.

Parks is theCollege of Medicinesassociate dean forResearch. He came to UCF in 2014 as director of the Burnett School of Biomedical Sciences after 20 years at the Wake Forest School of Medicine, where he was professor and chairman of the Department of Microbiology and Immunology. He earned his doctorate in biochemistry at the University of Wisconsin and was an American Cancer Society Fellow at Northwestern University.

Study title: Potent Inactivation of Human Respiratory Viruses Including SARS-CoV-2 by a Photoactivated Self-Cleaning Regenerative Antiviral Coating

Read the original:
UCF Researchers Prove that COVID Disinfectant Works in Latest Research Paper - UCF

Computation is the new experiment – ASBMB Today

After decades of playing second fiddle, computation is now taking center stage achieving critical insights that experimentation alone cannot provide. We are witnessing a dramatic rise in artificial intelligencebased methods coupled with year-on-year improvements of physics-based approaches. We now can fold a protein accurately from sequence alone!

Game-changing methods in protein and enzyme design are hurtling toward us. Scientists now can integrate numerous experimental data sets into computational models to explore previously unseen elements at (and across) scales never before achieved. Computational simulations are rewriting textbooks from molecules to system dynamics and function. Machine learning is transforming drug design and development.

All in all, you will not find a symposium at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, filled with more excitement and possibility than ours. Buckle up for a thrilling ride in March in Seattle!

Keywords: Artificial intelligence, structural biology, simulation, drug discovery, bioinformatics, systems biology, machine learning.

Who should attend: All who want to find out how computation is transforming biological problem-solving.

Theme song: Respect by Aretha Franklin, because computation deserves it.

This session is powered by a powerful flux capacitor.

Structure determinationDebora Marks,Harvard Medical SchoolRommie E. Amaro (chair),University of California, San DiegoRamanathan Arvind,Argonne National Laboratory; University of ChicagoJason Perry,Gilead Sciences Inc.

Drug designJohn Chodera,Sloan Kettering InstituteDavid Baker,University of WashingtonSteve Capuzzi,Vertex PharmaceuticalsCelia Schiffer (chair),University of Massachusetts Chan Medical School

Bioinformatics / Systems biologyMarian Walhout,University of Massachusetts Chan Medical SchoolJanet George,Intel CorporationIvet Bahar (chair),University of Pittsburgh School of MedicineHenry van dem Bedam,AtomWise Inc.

Follow this link:
Computation is the new experiment - ASBMB Today

Researchers discover toxin that kills bacteria in unprecedented ways – ASBMB Today

McMaster researchers have discovered a previously unknown bacteria-killing toxin that could pave the way for a new generation of antibiotics.

The study, led by John Whitney at the Michael G. DeGroote Institute for Infectious Disease Research, shows that the bacterial pathogen Pseudomonas aeruginosa, known to cause hospital-acquired infections such as pneumonia, secretes a toxin that has evolved to kill other species of bacteria.

Courtesy of Blake Dillon/McMaster University

John Whitney (right) and Nathan Bullen have studied this toxin for nearly three years.

For Whitney, the key aspect of his discovery is not just that this toxin kills bacteria, but how it does so.

This research is significant, because it shows that the toxin targets essential RNA molecules of other bacteria, effectively rendering them non-functional, says Whitney, an associate professor in the department of biochemistry and biomedical sciences.

Like humans, bacteria require properly functioning RNA in order to live.

First study author Nathan Bullen, a graduate student in biochemistry and biomedical sciences, describes it as a total assault on the cell because of the number of essential pathways depend on functional RNAs.

Whitney and Bullen, together with colleagues at Imperial College London and the University of Manitoba, have studied this toxin for nearly three years to understand exactly how it functions at a molecular level.

This is the graphical abstract for the team's paper, "An ADP-ribosyltransferase toxin kills bacterial cells by modifying structured non-coding RNAs."

The breakthrough, published in the journalMolecular Cell, was achieved by Bullen after rigorous experimentation on common targets of toxins, such as protein and DNA molecules, before eventually testing the toxin against RNA.

This discovery breaks well-established precedents set by protein-targeting toxins secreted by other bacteria, such as those that cause cholera and diphtheria.

Researchers say that this development holds great potential for future research that could eventually lead to new innovations that combat infection-causing bacteria.

Whitney says future antibiotic development can build on the newly discovered vulnerability.

This article was republished with permission from the Institute for Infectious Disease Research at McMaster University. Read the original.

Visit link:
Researchers discover toxin that kills bacteria in unprecedented ways - ASBMB Today

How a complex molecule moves iron through the body – ASBMB Today

New research provides fresh insight into how an important class of molecules are created and moved in human cells.

For years, scientists knew that mitochondria specialized structures inside cells in the body that are essential for respiration and energy production were involved in the assembly and movement of iron-sulfur cofactors, some of the most essential compounds in the human body. But until now, researchers didnt understand how exactly the process worked.

New research, published in the journal Nature Communications, found that these cofactors are moved with the help of a substance called glutathione, an antioxidant that helps prevent certain types of cell damage by transporting these essential iron cofactors across a membrane barrier.

Mechanism of cluster transport by Atm1.

Glutathione is especially useful as it aids in regulating metals like iron, which is used by red blood cells to make hemoglobin, a protein needed to help carry oxygen throughout the body, said James Cowan, co-author of the study and a distinguished university professor emeritus in chemistry and biochemistry at Ohio State.

Iron compounds are critical for the proper functioning of cellular biochemistry, and their assembly and transport is a complex process, Cowan said. We have determined how a specific class of iron cofactors is moved from one cellular compartment to another by use of complex molecular machinery, allowing them to be used in multiple steps of cellular chemistry.

Iron-sulfur clusters are an important class of compounds that carry out a variety of metabolic processes, like helping to transfer electrons in the production of energy and making key metabolites in the cell, as well as assisting in the replication of our genetic information.

But when these clusters don't work properly, or when key proteins cant get them, then bad things happen, Cowan said.

If unable to function, the corrupted protein can give rise to several diseases, including rare forms of anemia, Friedreichs ataxia (a disorder that causes progressive nervous system damage), and a multitude of other metabolic and neurological disorders.

So to study how this essential mechanism works, researchers began by taking a fungus called C. thermophilum, identifying the key protein molecule of interest, and producing large quantities of that protein for structural determination. The study notes that the protein they studied within C. thermophilum is essentially a cellular twin of the human protein ABCB7, which transfers iron-sulfur clusters in people, making it the perfect specimen to study iron-sulfur cluster export in people.

By using a combination of cryo-electron microscopy and computational modeling, the team was then able to create a series of structural models detailing the pathway that mitochondria use to export the iron cofactors to different locations inside the body. While their findings are vital to learning more about the basic building blocks of cellular biochemistry, Cowan said hes excited to see how their discovery could later advance medicine and therapeutics.

By understanding how these cofactors are assembled and moved in human cells, we can lay the groundwork for determining how to prevent or alleviate symptoms of certain diseases, he said. We can also use that fundamental knowledge as the foundation for other advances in understanding cellular chemistry.

This article was republished with permission from The Ohio State University. Read the original.

Go here to see the original:
How a complex molecule moves iron through the body - ASBMB Today

Role of Chitosan and Chitosan-Based Nanomaterials in Plant Sciences: Nanomaterial-Plant Interactions – The Physiological, Morphological, Biochemical…

DUBLIN--(BUSINESS WIRE)--The "Role of Chitosan and Chitosan-Based Nanomaterials in Plant Sciences. Nanomaterial-Plant Interactions" book from Elsevier Science and Technology has been added to ResearchAndMarkets.com's offering.

Role of Chitosan and Chitosan-Based Nanomaterials in Plant Sciences explores the physiological, morphological, biochemical and molecular regulation of chitosan and chitosan-based nanoparticles in plants in normal conditions, as well as during different stresses, and their probable mechanism of operation in the tolerance mechanism.

The book stimulates further research in the field of chitosan and will foster further interests for researchers, academicians and scientists worldwide. Nanotechnology is being used widely in all disciplines of science and technology, including plant sciences.

Chitosan has widely been reported as a beneficial organic compound for the growth and developments of plants and it plays a protective role for the plants against abiotic and biotic stresses. Yet there are very few books available that deal exclusively with Chitosan and Chitosan based nanoparticles impacts on plants respectively.

Key Topics Covered:

For more information about this book visit https://www.researchandmarkets.com/r/mbi2dq

Read the original:
Role of Chitosan and Chitosan-Based Nanomaterials in Plant Sciences: Nanomaterial-Plant Interactions - The Physiological, Morphological, Biochemical...

Atavistik Bio Announces Formation of Scientific Advisory Board – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Atavistik Bio, a pre-clinical biotechnology company that is leveraging their scalable and systematic platform to identify novel regulatory sites on proteins to restore function in disease, announced the formation of its Scientific Advisory Board (SAB) comprised of distinguished leaders in protein sciences, inborn errors of metabolism, and cancer.

We are proud and honored to have these accomplished scientific leaders join our Scientific Advisory Board, said Marion Dorsch, President and CSO of Atavistik Bio. Together, they bring a wealth of knowledge and experience for Atavistik Bio as we leverage our powerful screening and analytics platforms to unlock the potential of protein-metabolite interactions with the goal to bring transformative therapies to patients. Atavistik Bio looks forward to the input of these outstanding scientists and their contribution to our research and development efforts. Feedback and collaboration with our SAB will be critical to advance our efforts to develop therapies to patients in need. It is a very exciting time for all of us at Atavistik Bio.

The founding members of the Atavistik Bio Scientific Advisory Board are:

Dr. Ralph DeBerardinis is Chief of Pediatric Genetics and Metabolism at UT Southwestern Medical Center (UTSW) and Director of the Genetic and Metabolic Disease Program at Childrens Medical Center Research Institute at UTSW (CRI). His laboratory studies the role of altered metabolic pathways in human diseases, including cancer and pediatric inborn errors of metabolism. Work from the DeBerardinis laboratory has produced new insights into disease mechanisms in numerous metabolic diseases, including by defining unexpected fuel preferences in human cancer and uncovering new metabolic vulnerabilities in cancer cells. Dr. DeBerardinis is a Howard Hughes Medical Institute Investigator and has received numerous awards including the William K. Bowes, Jr. Award in Medical Genetics, the National Cancer Institutes Outstanding Investigator Award, The Academy of Medicine, Engineering & Science of Texass Edith and Peter ODonnell Award in Medicine, and the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Center. He has been elected to the National Academy of Medicine and the Association of American Physicians.

Dr. DeBerardinis received a BS in Biology from St. Josephs University in Philadelphia before earning MD and PhD degrees from the University of Pennsylvanias School of Medicine. He completed his medical residency and post-doctoral training at The Childrens Hospital of Philadelphia (CHOP) in Pediatrics, Medical Genetics and Clinical Biochemical Genetics.

Dr. Jared Rutter is a Distinguished Professor of Biochemistry and holds the Dee Glen and Ida Smith Endowed Chair for Cancer Research at the University of Utah where he has been on the faculty since 2003. His laboratory has identified the functions of several previously uncharacterized mitochondrial proteins, including the discovery of the long-sought mitochondrial pyruvate carrier. This knowledge has demonstrated that this critical metabolic step is impaired in a variety of human diseases, including cancer and cardiovascular disease. In addition, the Rutter lab is taking multiple approaches to understand how metabolic state influences cell fate and cell behavior decisions. Dr. Rutter has been an Investigator of the Howard Hughes Medical Institute since 2015 and serves as co-Director of the Diabetes and Metabolism Center at the University of Utah and co-Leader of the Nuclear Control of Cell Growth and Differentiation at Huntsman Cancer Institute.

Dr. Rutter performed undergraduate studies at Brigham Young University and received his PhD from the University of Texas Southwestern Medical Center in 2001, working with Dr. Steve McKnight. After receiving his PhD, he spent 18 months as the Sara and Frank McKnight Independent Fellow of Biochemistry before joining the faculty at the University of Utah.

Karen Allen, Ph.D. is Professor and Chair of Chemistry at Boston University. For over 25 years, she has led research teams at Boston University, in the Departments of Physiology and Biophysics at the School of Medicine, and Chemistry. She is also a Professor of Material Science and Engineering and on the faculty of the Bioinformatics program at Boston University. The structure-aided design approach in the Allen lab encompasses the use of macromolecular X-ray crystallography, small-angle X-ray scattering, molecular modeling, and kinetics.

Karen received her B.S. degree in Biology, from Tufts University and her Ph.D. in Biochemistry from Brandeis University in the laboratory of the mechanistic enzymologist, Dr. Robert H. Abeles. Following her desire to see enzymes in action she pursued X-ray crystallography during postdoctoral studies as an American Cancer Society Fellow in the laboratory of Drs. Gregory A. Petsko and Dagmar Ringe.

Kivanc Birsoy, Ph.D. is a Chapman-Perelman Associate Professor at Rockefeller University. His research at Rockefeller focuses on how cancer cells rewire their metabolic pathways to adapt to environmental stresses during tumorigenesis and other pathological states. He is the recipient of numerous awards, including the Leukemia and Lymphoma Society Special Fellow award, Margaret and Herman Sokol Award, NIH Career Transition Award, Irma Hirschl/Monique Weill-Caulier Trusts Award, Sidney Kimmel Cancer Foundation Scholar Award, March of Dimes Basil OConnor Scholar Award, AACR NextGen award for Transformative Cancer Research, Searle Scholar, Pew-Stewart Scholarship for Cancer Research and NIH Directors New Innovator Award.

Kivanc received his undergraduate degree in Molecular Genetics from Bilkent University in Turkey in 2004 and his Ph.D. from the Rockefeller University in 2009, where he studied the molecular genetics of obesity in the laboratory of Jeffrey Friedman. In 2010, he joined the laboratory of David Sabatini at the Whitehead Institute of Massachusetts Institute of Technology (MIT) where he combined forward genetics and metabolomics approaches to understand how different cancer types rewire their metabolism to adapt nutrient deprived environments.

Benjamin Cravatt, Ph.D. is the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in cancer and the nervous system. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Wolf Prize in Chemistry, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. Ben is a co-founder of several biotechnology companies, including Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), Vividion Therapeutics (Acquired by Bayer Pharmaceuticals), Boundless Bio, Kisbee Therapeutics, and Kojin Therapeutics.

Ben obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.

The SAB will be co-chaired by Dr. DeBerardinis and Dr. Rutter, the scientific founders of Atavistik Bio, and work closely with the company to advance their leading-edge metabolite protein screening platform discovery programs. Im delighted to be appointed Co-Chair of Atavistik Bios Scientific Advisory Board, and to be part of such a distinguished group of experts, said Dr. DeBerardinis. Together we aim to guide Atavistik Bio through the development of its pipeline while maximizing the potential of the companys technology platform, stated Dr. Rutter.

About Atavistik Bio

Atavistik Bio is a pre-clinical biotechnology company that is harnessing the power of protein-metabolite interactions to add a new lens to drug discovery with the aim of transforming the lives of patients. By leveraging its optimized Atavistik Metabolite Protein Screening (AMPS) platform and computational approaches, Atavistik Bio aims to evaluate metabolite-protein interactions by screening proteins with their proprietary metabolite library to determine where binding sites with biological relevance might exist. This will enable Atavistik Bio to build an extensive protein-metabolite database map (the Interactome) to reveal unique insights into the crosstalk between metabolite-protein pathways that were previously thought to be unrelated. Utilizing advanced informatics tools, deep expertise in chemistry and computationally rich structure-based drug design, Atavistik Bio will be able to identify and understand the role of these interactions across important biological and disease-relevant pathways to drive the discovery of novel therapeutics with an initial focus on inborn errors of metabolism and cancer. Atavistik Bio is located in Cambridge, Massachusetts. For more information, visit http://www.atavistikbio.com.

See original here:
Atavistik Bio Announces Formation of Scientific Advisory Board - Business Wire

Decipher GC Validation in Patients Receiving SRT Without Hormone Therapy after Radical Prostatectomy – Physician’s Weekly

The Decipher genomic classifier (GC) has demonstrated the ability to predict prostate cancer outcomes independently. Researchers sought to verify the GC in a randomized phase III trial of dose-escalated salvage radiotherapy (SRT) following radical prostatectomy.

In a phase III trial of 350 men with biochemical recurrence after radical prostatectomy who were randomly assigned to 64 Gy or 70 Gy without concurrent hormonal therapy or pelvic nodal RT, a clinical-grade whole-transcriptome assay was performed on radical prostatectomy samples obtained from patients enrolled in Swiss Group for Clinical Cancer Research (SAKK) 09/10. A predetermined statistical strategy was created to determine how the GC will affect clinical results. The main outcome was biochemical development; the secondary outcomes were clinical development and delay in hormone treatment. Age, T-category, Gleason score, post radical prostatectomy persistent prostate-specific antigen (PSA), PSA at randomization, and randomization arm were all adjusted in multivariable analyses to take competing hazards into account.

With a median follow-up of 6.3 years, the analytic cohort of 226 patients was typical of the whole experiment (interquartile range 6.1-7.2 years). The GC (high versus low-intermediate) was independently correlated with biochemical progress (subdistribution hazard ratio (sHR) 2.26, 95% CI1.42-3.60; P<0.001), clinical progress (HR 2.29, 95% CI 1.32-3.98; P=0.003), and hormone therapy use (sHR 2.99, 95% CI 1.55-5.76; P=0.001). Compared to GC low-intermediate patients, GC high patients had 5-year independence from biochemical advancement of 45% as opposed to 71%. Both the general cohort and individuals with lower vs. higher GC scores did not benefit from the dose increase.

The predictive value of the GC has been proven in this investigation, which is the first modern randomized controlled trial in patients treated with early SRT without concomitant hormone treatment or pelvic nodal RT. High-GC patients were more than twice as likely to develop biochemical and clinical progression and undergo salvage hormone treatment than lower-GC patients, independent of common clinicopathologic factors and RT dosage. These findings support the therapeutic utility of Decipher GC for individualized concurrent systemic treatment in the context of postoperative salvage.

Reference: annalsofoncology.org/article/S0923-7534(22)01205-4/fulltext

Excerpt from:
Decipher GC Validation in Patients Receiving SRT Without Hormone Therapy after Radical Prostatectomy - Physician's Weekly